Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes - Seite 3
Sernova and Evotec are going to hold a joint conference call on the transaction. The conference call will be held in English.
Conference call details
Date: Tuesday, 17 May 2022
Time: 02.30 pm CEST (08.30 am EDT, 01.30 pm BST)
US Toll Free: 1-877-704-4453
International: 1-201-389-0920
Conference ID: 13730121
A simultaneous slide presentation will be available under the following link: https://viavid.webcasts.com/starthere.jsp?ei=1550130&tp_key=3de87cce1d
About Evotec and iPSC
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya
Yamanaka's lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded
the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent". Pluripotent stem cells hold great promise in the field of
regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a
single source of cells that could be used to replace those lost to damage or disease.
Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Company's proprietary EVO cells platform.
Lesen Sie auch
About Sernova Corp and the Cell Pouch System cell therapy platform
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell
derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases
treated through replacement of proteins or hormones missing or in short supply within the body.